Azvudine hydrochloride

  • CAT Number: I015022
  • CAS Number: 1333126-31-0
  • Molecular Formula: C₉H₁₂ClFN₆O₄
  • Molecular Weight: 322.68
  • Purity: ≥95%
Inquiry Now

Azvudine hydrochloride(Cat No.:I015022) is a potent nucleoside reverse transcriptase inhibitor (NRTI) that exhibits antiviral activity against HIV, HBV, and HCV. It is highly effective against HIV-1 (with EC50s ranging from 0.03 to 6.92 nM) and HIV-2 (with EC50s ranging from 0.018 to 0.025 nM). Azvudine hydrochloride is also able to inhibit NRTI-resistant viral strains, making it a promising candidate for the treatment of viral infections.

Catalog Number I015022
CAS Number 1333126-31-0
Molecular Formula

C₉H₁₂ClFN₆O₄

Purity 95%
IUPAC Name 4-amino-1-[(2R,3S,4R,5R)-5-azido-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one;hydrochloride
InChI InChI=1S/C9H11FN6O4.ClH/c10-5-6(18)9(3-17,14-15-12)20-7(5)16-2-1-4(11)13-8(16)19;/h1-2,5-7,17-18H,3H2,(H2,11,13,19);1H/t5-,6-,7+,9+;/m0./s1
InChIKey MKMLHJHSIBILJH-DBSFTZRASA-N
SMILES C1=CN(C(=O)N=C1N)C2C(C(C(O2)(CO)N=[N+]=[N-])O)F.Cl
Reference

[1]. Wang RR, et al. Azvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug combination features and better inhibition on drug-resistant strains than lamivudine in vitro. PLoS One. 2014 Aug 21;9(8):e105617.

Request a Quote

Contact Us at MuseChem

We are committed to providing you with reliable, cost-effective solutions for your chemical needs, while ensuring your safety and comfort. Our team of experts is always available to answer your questions and help you navigate the complexities of the chemical industry.

Whether you're looking for a specific product or need help with a custom synthesis project, we're here to help you discover a new world of chemical possibilities. Contact us today to learn more about how we can assist you with all of your chemical needs.

Our goal is to make the process of ordering chemicals as seamless and hassle-free as possible. Let us know how we can assist you, and we'll get back to you as soon as possible. We look forward to hearing from you!